Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose nimotuzumab plus chemoradiotherapy versus chemoradiotherapy alone in locally advanced esophageal cancer
ChiCTR-TRC-14004997Phase 2Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jun 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nimotuzumab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Fujian Medical University Cancer Hospital. Primary endpoints: Objective response rate and Disease control rate. Started Jun 2014; status: recruiting.
02
Drugs
nimotuzumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR-TRC-14004997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-14004997.